Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study

Affiliations

¹ Intensive Care Unit, The Jikei University Hospital, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
² Intensive Care Unit, The Jikei University Hospital, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan. tofujii-tky@umin.net.
³ Department of Clinical Engineering Technology, The Jikei University Hospital, Tokyo, Japan.
⁴ Department of Pharmacy, The Jikei University Hospital, Tokyo, Japan.
⁵ Department of Anesthesiology, The Jikei University Hospital, Tokyo, Japan.

Published Erratum

Shinya Kameda et al. BMC Nephrol. 2023.

. 2023 Jan 26;24(1):22.

doi: 10.1186/s12882-023-03067-8.

¹ Intensive Care Unit, The Jikei University Hospital, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
² Intensive Care Unit, The Jikei University Hospital, 3-19-18 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan. tofujii-tky@umin.net.
³ Department of Clinical Engineering Technology, The Jikei University Hospital, Tokyo, Japan.
⁴ Department of Pharmacy, The Jikei University Hospital, Tokyo, Japan.
⁵ Department of Anesthesiology, The Jikei University Hospital, Tokyo, Japan.

No abstract available

Erratum for

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.
Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, Uezono S. Kameda S, et al. BMC Nephrol. 2023 Jan 16;24(1):12. doi: 10.1186/s12882-023-03060-1. BMC Nephrol. 2023. PMID: 36642717 Free PMC article.

1. Kameda S, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC Nephrol. 2023;24:12. doi: 10.1186/s12882-023-03060-1. - DOI - PMC - PubMed